보고서 요약(국문)

개요
전 세계 1형 알파-1 항트립신 결핍증 치료 시장은 2022년 xx억 달러에 달했으며, 2023년부터 2030년까지 연평균 xx%의 성장률을 보이며 2030년에는 xx억 달러에 이를 것으로 예상됩니다.
전 세계 1형 알파-1 항트립신 결핍증 치료 시장은 여러 요인의 영향으로 상당한 성장과 변화를 보여왔습니다. 알파-1 항트립신 결핍증(AAT)이 있는 사람은 폐 질환을 비롯한 여러 질병에 걸릴 위험이 높아집니다. AAT는 간에서 생성되는 단백질로 폐를 보호하는 역할을 합니다. 체내에서 AAT가 충분히 생성되지 않으면 흡연, 대기 오염, 환경 먼지 등으로 인한 폐 손상에 더욱 취약해집니다.
특히 개발도상국을 중심으로 한 정부 투자와 연구는 첨단 제품 및 치료법의 활용을 촉진하고 전 세계 1형 알파-1 항트립신 결핍증 치료 시장의 성장을 견인할 것입니다. 이러한 혁신적인 제품에는 증상 관리를 위한 증강 요법과 같은 새로운 치료법이 포함됩니다.

시장 동향: 성장 동력 및 제약 요인
치료 관련 사업 확대 및 규제 승인
선진국들은 높은 투자, 소득 수준 향상, 인프라 개발에 힘입어 의료 부문이 빠르게 발전하고 있습니다. 여러 국가에서 알파-1 항트립신 결핍증(AATD) 치료에 대한 수요가 연구 결과의 긍정적인 결과로 인해 상당 부분 증가했습니다. 각국의 제품 출시 관련 규제 승인은 시장 성장을 견인하는 중요한 요인이 될 것입니다.
2021년 11월 24일, 스페인의 알파-1 항트립신 결핍증(AATD) 환자들은 세계적인 혈장 유래 의약품 제조업체이자 110년 이상 사람들의 건강과 삶의 질 향상에 기여해 온 그리폴스(Grifols) 덕분에 새로운 가정 내 주입 치료 옵션을 이용할 수 있게 되었습니다. 그리폴스의 알파케어(AlfaCare) 이니셔티브의 일환으로 제공되는 이 새로운 서비스는 치료 접근성을 개선하고 치료 편의성을 높이는 것을 목표로 합니다. 자격을 갖춘 전문가를 통해 AATD 환자에게 교육, 정서적 지원 및 도움을 포함하는 통합적이고 맞춤화된 프로그램을 제공합니다.
2023년 5월 16일, 희귀 및 중증 질환 치료제를 시판 중인 글로벌 바이오제약 회사인 카마다(Kamada Ltd.)에 따르면, 알파-1 프로테아제 억제제(인간 유래)인 글라시아(Glassia)가 중증 유전성 알파-1 항트립신 결핍증(AA)으로 인한 임상적으로 진단된 성인 폐기종 환자의 유지 치료 외에 지속적인 증강 요법에 대한 스위스 시판 승인을 받았습니다.
또한, 알파-1 항트립신 결핍증 관리를 위한 새로운 치료법 또는 약물의 사용이 증가하고 있습니다. 사람들의 인식 제고와 혁신적인 제품 개발을 위한 연구 증가는 제1형 알파-1 항트립신 결핍증 치료 시장 성장을 이끄는 주요 요인이 될 것입니다.
증강 요법과 관련된 부작용
알파-1 항트립신 결핍증에 대한 증강 요법에서 여러 가지 부작용이 보고되었지만, 대부분의 환자는 심각한 문제를 겪지 않습니다. 피로감이나 독감 유사 증상이 가장 흔한 부작용이며, 주입 후 최대 24시간 동안 지속될 수 있습니다. 이러한 증상은 주입 속도를 늦추면 완화되거나 완전히 사라질 수 있습니다.
일부 알파-1 항트립신 결핍증 환자에게서 나타나는 경미한 알레르기 반응과 유사한 증상으로는 가려움증, 두드러기, 발진, 호흡곤란, 가슴 답답함, 천명 등이 있습니다. 많은 환자들이 주입 전에 베나드릴과 같은 알레르기 약을 복용하면 증강 요법을 계속 받을 수 있습니다. 부작용이 너무 심해 증강 요법 처방을 완전히 중단해야 하는 경우는 매우 드뭅니다.
세분화 분석
전 세계 1형 알파-1 항트립신 결핍증 치료 시장은 치료 유형, 투여 경로, 최종 사용자 및 지역별로 세분화됩니다.

증강 요법 부문은 시장 점유율의 약 45%를 차지했습니다.
중증 제1형 알파-1 항트립신(AAT) 결핍증이 있는 폐기종 환자는 증강 요법(때로는 대체 요법이라고도 함)의 혜택을 받을 수 있습니다. AAT 결핍증 환자의 폐에서 알파-1 항트립신(AAT) 수치는 건강한 기증자의 혈액에서 얻은 알파-1 항트립신 단백질을 사용하여 증가합니다. AAT는 건강한 사람의 면역 체계로 인한 폐 손상을 방지합니다. AAT 증강 요법은 AAT 결핍증 환자의 폐에서 AAT 양을 증가시켜 추가적인 폐 손상을 예방하는 데 도움을 줍니다.
2023년 7월 13일, 알파-1 항트립신(AAT) 결핍증이 있는 폐기종 환자에게 두 가지 다른 그리폴 투여 요법을 매주 투여했을 때 폐 조직 손실이 더 점진적으로 진행되는지 여부를 확인하기 위한 3상 임상 연구가 진행되었습니다. 혈장 유래 의약품 주요 제조업체 중 하나인 그리폴스(Grifols)에 따르면, 프로라스틴-C(Prolastin-C)는 목표 환자 339명 전원을 임상시험에 등록했습니다.
현재까지 진행된 알파-1 항트립신(AAT) 증강 치료에 대한 최대 규모의 무작위 배정, 위약 대조, 이중 맹검 연구인 SPARTA 연구에 따르면, 프로라스틴-C는 위약 대비 두 가지 유효 용량을 주 1회 투여하여 AAT 단백질 수치를 높임으로써 알파-1 항트립신 결핍증 환자의 폐기종 진행 속도를 유의미하게 늦출 가능성이 있습니다.
지역별 시장 점유율
북미는 2022년 시장 점유율의 약 40%를 차지했습니다.
의료 분야에서 1형 알파-1 항트립신 결핍증 치료에 대한 수요가 증가함에 따라 북미 제조업체들은 사업 확장의 기회를 갖고 있습니다. 북미에는 많은 생산자와 공급업체가 있으며, 이 지역의 빠른 경제 성장으로 산업 생산이 확대되어 1형 알파-1 항트립신 결핍증 치료에 대한 수요를 견인하고 있습니다.

의료비 지출 증가, 연구 활동 확대, 기술 발전 및 다양한 치료법 개발, 그리고 이 지역 전반에 걸친 제약 및 생명공학 기업 설립 증가는 제1형 알파-1 항트립신 결핍증 치료 시장 점유율 성장에 기여하고 있습니다. 프로라스틴-C와 같은 다양한 혁신적인 신약 치료법에 대한 인식이 높아짐에 따라 이 지역 시장은 성장하고 있습니다. 앞서 언급한 요소들은 북미가 세계 시장에서 주도적인 위치를 차지하고 있음을 더욱 뒷받침합니다.
북미는 미국을 중심으로 전 세계 제1형 알파-1 항트립신 결핍증 치료 시장에서 핵심적인 역할을 계속하고 있습니다. 인프라 개발 및 투자를 장려하는 정부 정책과 첨단 기술 발전에 대한 집중적인 투자는 미국 내 제1형 알파-1 항트립신 결핍증 치료 수요를 촉진했습니다. 미국은 제1형 알파-1 항트립신 결핍증 치료 수요를 자극하는 여러 정책 및 연구를 적극적으로 추진해 왔습니다.

COVID-19 영향 분석
2019년 말 발생한 COVID-19 팬데믹은 전 세계 산업, 특히 제1형 알파-1 항트립신 결핍증 치료제 시장에 전례 없는 어려움을 초래했습니다. 각국이 봉쇄 조치, 공급망 차질, 경제 활동 위축에 직면하면서 다양한 의료기기의 주요 소비자인 제약 부문은 심각한 타격을 입었습니다. 2020년 초부터 시작된 팬데믹으로 인한 광범위한 봉쇄와 제한 조치는 전 세계 여러 사업에 영향을 미쳤습니다.
주요 의료기기 제조업체들은 생산을 중단하고 COVID-19 관리에 집중하면서 제1형 알파-1 항트립신 결핍증 치료제 수요가 급감했습니다. 그러나 현재 여러 연구가 재개되었고, 기업들은 제품의 안전성과 효능에 대한 임상 시험을 다시 시작했습니다. 전반적으로, 전 세계 1형 알파-1 항트립신 결핍증 치료 시장에 대한 팬데믹의 영향은 비교적 완만할 것으로 예상되며, 증강 요법 및 1형 알파-1 항트립신 결핍증 관리를 위한 기타 프로그램과 같은 새로운 치료법에 대한 지속적인 수요와 연구로 인해 시장은 꾸준히 성장할 것으로 전망됩니다.
치료 유형별
• 증강 요법
o 프로라스틴-C
o 아랄라스트
o 제마이라
o 글라시아
• 약물 치료
o 기관지 확장제
 이프라트로피움 브로마이드
 테오필린
o 항생제
 독시사이클린
 답손
• 산소 요법
• 금연 요법
• 기타
투여 경로별
• 흡입
• 정맥 주사
• 기타
최종 사용자별
• 병원
• 외래 수술 센터
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 개발 사항
• 2023년 4월 4일, 다케다 제약의 알파-1 항트립신 결핍 관련 간질환(AATD-LD) 치료제 파지르시란(TAK-999/ARO-AAT)의 3상 REDWOOD 임상 연구에서 애로우헤드 제약(Arrowhead Pharmaceuticals Inc.)은 첫 번째 환자에게 투약이 완료되었다고 발표했습니다. 다케다는 이 중요한 임상 시험이 시작되는 즉시 애로우헤드에 4천만 달러의 혁신 치료제 지원금을 지급할 예정입니다. 2021년 7월, 미국 식품의약국(FDA)은 파지르시란을 AATD-LD 치료제로 혁신 치료제 지정(Breakthrough Therapeutic Designation)했습니다.
• 2022년 10월 17일, 종양학 및 희귀 질환에 중점을 둔 임상 단계 바이오제약 회사인 메레오 바이오파마 그룹(Mereo BioPharma Group plc)은 실험 단계의 경구용 호중구 엘라스타제 억제제인 알벨레스타트(MPH-966)에 대해 미국 식품의약국(FDA)의 신속심사(Fast Track) 지정을 받았습니다. 메레오는 연말쯤 FDA와의 2상 종료 회의에서 AATD 관련 폐 질환 치료제인 알벨레스타트의 허가 승인을 위한 임상시험 계획, 특히 신속 승인 경로 가능성에 대해 논의할 예정입니다.
경쟁 환경
주요 글로벌 시장 참여 기업으로는 카마다 제약, 다케다 제약, CSL, 버텍스 제약, 그리폴스, 애로우헤드 제약, 다이서나 제약, 인히브릭스, 웨이브 라이프 사이언스, 메레오 바이오파마 그룹 등이 있습니다.
보고서 구매 이유

• 치료법, 투여 경로, 최종 사용자 및 지역별 글로벌 AATD 치료 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악하기 위함입니다.

• 시장 동향 및 공동 개발 분석을 통해 사업 기회를 발굴하기 위함입니다.

• 모든 세그먼트를 포함한 제1형 알파-1 항트립신 결핍증 치료 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트.

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 엑셀 파일 제공.

글로벌 제1형 알파-1 항트립신 결핍증 치료 시장 보고서는 약 61개의 표, 58개의 그림, 186페이지 분량입니다.
주요 독자층 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global type 1 alpha-1 antitrypsin deficiency treatment market reached US$ xx billion in 2022 and is expected to reach US$ xx billion by 2030, growing with a CAGR of xx% during the forecast period 2023-2030.
The global type 1 alpha-1 antitrypsin deficiency treatment market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. The chance of developing lung and additional illnesses increases if the person have an AAT deficiency. AAT is a protein produced in the liver that aids in lung defense. The lungs are more vulnerable to injury from smoking, air pollution, and environmental dust if the body fails to produce enough AAT.
Government investments and research, particularly in developing economies, will continue to drive utilization of advanced products or therapies and boost the global type 1 alpha-1 antitrypsin deficiency treatment market. The respective innovative products includes the use of novel treatments such as augmentation therapy for better management.
Market Dynamics: Drivers & Restraints
Growing initiatives and regulatory approvals for treatment
Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for type 1 alpha-1 antitrypsin deficiency treatment owing to the positive outcomes in research. Various regulatory approvals for product launch among different countries will be a crucial factor driving the growth of the market.
On November 24, 2021, Alpha-1 antitrypsin deficiency (AATD) patients in Spain now have a new home-infusion treatment option thanks to Grifols, one of the top manufacturers of plasma-derived medications in the world with more than 110 years of experience improving people's health and quality of life. Within Grifols' AlfaCare initiative, this new service seeks to improve treatment accessibility and the convenience of its administration. Through the use of qualified specialists, it provides AATD patients with an integrated, tailored program that includes instruction, emotional support, and help.
On May 16, 2023, according to Kamada Ltd., an industrial phase global biopharmaceutical company with a collection of marketed medications indicated for rare and serious illnesses, Glassia, an Alpha-1 Proteinase Inhibitor (Human), received approval for advertising in Switzerland for ongoing augmentation in addition to maintenance treatment in adulthood having clinically diagnosed emphysema resulting from severe inherited Alpha-1 antitrypsin deficiency (AA).
Furthermore, the rising utilization of novel therapies or drugs for the management of alpha-1 antitrypsin deficiency. Rising awareness among people and increasing research for innovative product development will be a major factor driving the growth of the type 1 alpha-1 antitrypsin deficiency treatments market.
Side effects associated with the augmentation therapy
Alphas have documented a number of adverse effects of augmentation therapy, however the majority never suffer any substantial problems. Fatigue or flu-like symptoms are the most typical side effect, and they might last up to 24 hours after an infusion. These symptoms can frequently be lessened or even eliminated by slowing down the infusion rate.
Some of the indications that some Alphas experience that resemble minor allergic responses include itching, hives, rash, dyspnea, heaviness in the chest, and wheezing. Many individuals can continue receiving augmentation therapy if they take an allergy medication like Benadryl before their infusions. Very seldom do side effects become so severe that an Alpha has to entirely stop taking their augmentation prescription.
Segment Analysis
The global type 1 alpha-1 antitrypsin deficiency treatment market is segmented based on treatment, route of administration, end user and region.
Augmentation Therapy segment accounted for approximately 45% of market share
Patients with significant type 1 alpha-1 antitrypsin (AAT) insufficiency who have emphysema may benefit from augmentation therapy, sometimes referred to as replacement therapy. The level of alpha-1 antitrypsin (AAT) in the lungs of patients having AAT deficiency is increased using alpha-1 antitrypsin protein obtained from the blood of healthy donors. AAT guards against lung damage caused by the immune system in healthy people. AAT augmentation therapy helps individuals with AAT deficiency increase the quantity of AAT in their lungs, preventing additional lung damage.
On July 13, 2023, a phase 3 clinical research to determine whether weekly administration of two different Grifols dosing regimens results in a more gradual loss of lung tissue in people with emphysema who have alpha-1-antitrypsin (AAT) deficiency (alpha-1). According to Grifols, one of the major manufacturers of medicines produced from plasma, Prolastin-C has enrolled all 339 of its target patients.
According to SPARTA, the biggest randomized, placebo-controlled, double-blind study on AAT augmentation treatment to date, Prolastin-C has the potential to significantly slow the progression of emphysema in alpha-1 patients through raising AAT protein levels through weekly administration of two effective dose levels in comparison to placebo.
Geographical Penetration
North America accounted for around 40% of market share in 2022
Due to the rising need for type 1 alpha-1 antitrypsin deficiency treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for type 1 alpha-1 antitrypsin deficiency treatment.
Increasing expenditure on healthcare and rising research studies, advancement of technologies and different kinds of therapies for management, and increase in pharmaceutical or biotechnology business establishment across the region are also contributing to the growth of type 1 alpha-1 antitrypsin deficiency treatment market share of this region. The market in this area is growing as people become more aware of various novel innovative therapies such as Prolastin-C. The aforementioned elements further attest to North America's hegemonic position in the world.
North America continues to be a key player in the global type 1 alpha-1 antitrypsin deficiency treatment market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for type 1 alpha-1 antitrypsin deficiency treatment in the U.S. United States have been proactive in executing several initiatives or researches, stimulating type 1 alpha-1 antitrypsin deficiency treatment demand.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global type 1 alpha-1 antitrypsin deficiency treatment market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various device designs, was significantly impacted. The widespread lockdowns and restrictions imposed by the pandemic, which began in early 2020, had an effect on a number of initiatives all around the world.
Major medical device industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for type 1 alpha-1 antitrypsin deficiency treatment. Now several research studies have been initiated and companies have again started trial for their products safety and efficacy. Overall, the impact of the pandemic on the global type 1 alpha-1 antitrypsin deficiency treatment market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for novel therapies, like augmenting therapies and other programs for management of type-1 alpha-1 antitrypsin deficiency.
By Treatment
• Augmentation Therapy
o Prolastin-C
o Aralast
o Zemaira
o Glassia
• Medication
o Bronchodilators
 Ipratropium Bromide
 Theophylline
o Antibiotics
 Doxycycline
 Dapsone
• Oxygen Therapy
• Smoking Cessation Therapy
• Others
By Route of Administration
• Inhaled
• Intravenous
• Others
By End User
• Hospitals
• Ambulatory Surgical Centers
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• On April 4, 2023, in Takeda's Phase 3 REDWOOD clinical investigation of fazirsiran (TAK-999/ARO-AAT) as the management of alpha-1 antitrypsin deficiency related liver disease (AATD-LD), Arrowhead Pharmaceuticals Inc. stated that the first patient has been dosed. Takeda will provide Arrowhead a $40 million breakthrough payment as soon as this crucial trial begins. In July 2021, the U.S. Food and Drug Administration awarded Fazirsiran Breakthrough Therapeutic Designation for the management of AATD-LD.
• On October 17, 2022, Alvelestat (MPH-966), an experimental oral neutrophil elastase inhibitor, has been given U.S. Food and Drug Administration (FDA) Fast Track designation by Mereo BioPharma Group plc, a clinical-stage biopharmaceutical firm with a focus on oncology and rare disorders. Around the end of the year, Mereo plans to meet with the FDA at the End-of-Phase 2 meeting to explore the planning of a registration-enabling trial for alvelestat as a cure for AATD-associated lung illness, including the potential for an expedited approval pathway.
Competitive Landscape
The major global players in the market include Kamada Pharmaceuticals, Takeda Pharmaceutical Company Limited, CSL, Vertex Pharmaceuticals Incorporated, Grifols, Arrowhead Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc, Inhibrx, Inc., Wave Life Sciences and Mereo Biopharma Group PLC among others.
Why Purchase the Report?
• To visualize the global type 1 alpha-1 antitrypsin deficiency treatment market segmentation based on treatment, route of administration, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of type 1 alpha-1 antitrypsin deficiency treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global type 1 alpha-1 antitrypsin deficiency treatment market report would provide approximately 61 tables, 58 figures and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Treatment
3.2. Snippet by Route of Administration
3.3. Snippet by End User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing initiatives and regulatory approvals for treatment
4.1.1.2. Rising technological advancements and developments
4.1.2. Restraints
4.1.2.1. Side effects associated with the augmentation therapy
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pricing Analysis
5.6. SWOT Analysis
5.7. Patent Analysis
5.8. Russia-Ukraine War Impact Analysis
5.9. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Treatment
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
7.1.2. Market Attractiveness Index, By Treatment
7.2. Augmentation Therapy*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Prolastin-C
7.2.4. Aralast
7.2.5. Zemaira
7.2.6. Glassia
7.3. Medication
7.3.1. Bronchodilators
7.3.1.1. Ipratropium Bromide
7.3.1.2. Theophylline
7.3.2. Antibiotics
7.3.2.1. Doxycycline
7.3.2.2. Dapsone
7.4. Oxygen Therapy
7.5. Smoking Cessation Therapy
7.6. Others
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Inhaled *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Intravenous
8.4. Others
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Ambulatory Surgical Centers
9.4. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Kamada Pharmaceuticals*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Takeda Pharmaceutical Company Limited
12.3. CSL
12.4. Vertex Pharmaceuticals Incorporated
12.5. Grifols
12.6. Arrowhead Pharmaceuticals, Inc.
12.7. Dicerna Pharmaceuticals, Inc.
12.8. Inhibrx, Inc.
12.9. Wave Life Sciences
12.10. Mereo Biopharma Group PLC
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Kamada Pharmaceuticals, 4.	Key Developments, Takeda Pharmaceutical Company Limited, CSL, Vertex Pharmaceuticals Incorporated, Grifols, Arrowhead Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Inhibrx, Inc., Wave Life Sciences, Mereo Biopharma Group PLC

표 목록 (Tables)

List of Tables

Table 1 Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, By Treatment, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, By End User, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, By Treatment, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, By Treatment, 2022-2031 (US$ Million)

Table 7 Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 9 Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, By End User, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, By End User, 2022-2031 (US$ Million)

Table 11 Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, By Treatment, 2023, 2027 & 2031 (US$ Million)

Table 14 North America Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 15 North America Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, By End User, 2022-2031 (US$ Million)

Table 16 North America Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 17 South America Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, By Treatment, 2022-2031 (US$ Million)

Table 18 South America Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 19 South America Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, By End User, 2022-2031 (US$ Million)

Table 20 South America Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, By Treatment, 2022-2031 (US$ Million)

Table 22 Europe Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 23 Europe Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, By End User, 2022-2031 (US$ Million)

Table 24 Europe Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Asia-Pacific Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, By Treatment, 2022-2031 (US$ Million)

Table 26 Asia-Pacific Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 27 Asia-Pacific Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, By End User, 2022-2031 (US$ Million)

Table 28 Asia-Pacific Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East & Africa Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, By Treatment, 2022-2031 (US$ Million)

Table 30 Middle East & Africa Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 31 Middle East & Africa Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, By End User, 2022-2031 (US$ Million)

Table 32 Kamada Pharmaceuticals: Overview

Table 33 Kamada Pharmaceuticals: Product Portfolio

Table 34 Kamada Pharmaceuticals: Key Developments

Table 35 Takeda Pharmaceutical Company Limited: Overview

Table 36 Takeda Pharmaceutical Company Limited: Product Portfolio

Table 37 Takeda Pharmaceutical Company Limited: Key Developments

Table 38 CSL: Overview

Table 39 CSL: Product Portfolio

Table 40 CSL: Key Developments

Table 41 Vertex Pharmaceuticals Incorporated: Overview

Table 42 Vertex Pharmaceuticals Incorporated: Product Portfolio

Table 43 Vertex Pharmaceuticals Incorporated: Key Developments

Table 44 Grifols: Overview

Table 45 Grifols: Product Portfolio

Table 46 Grifols: Key Developments

Table 47 Arrowhead Pharmaceuticals, Inc.: Overview

Table 48 Arrowhead Pharmaceuticals, Inc.: Product Portfolio

Table 49 Arrowhead Pharmaceuticals, Inc.: Key Developments

Table 50 Dicerna Pharmaceuticals, Inc.: Overview

Table 51 Dicerna Pharmaceuticals, Inc.: Product Portfolio

Table 52 Dicerna Pharmaceuticals, Inc.: Key Developments

Table 53 Inhibrx, Inc.: Overview

Table 54 Inhibrx, Inc.: Product Portfolio

Table 55 Inhibrx, Inc.: Key Developments

Table 56 Wave Life Sciences: Overview

Table 57 Wave Life Sciences: Product Portfolio

Table 58 Wave Life Sciences: Key Developments

Table 59 Mereo Biopharma Group PLC: Overview

Table 60 Mereo Biopharma Group PLC: Product Portfolio

Table 61 Mereo Biopharma Group PLC: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, 2022-2031 (US$ Million)

Figure 2 Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Share, By Treatment, 2022 & 2031 (%)

Figure 3 Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 4 Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Share, By End User, 2022 & 2031 (%)

Figure 5 Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Share, By Region, 2022 & 2031 (%)

Figure 6 Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Y-o-Y Growth, By Treatment, 2022-2031 (%)

Figure 7 Augmentation Therapy in Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, 2022-2031 (US$ Million)

Figure 8 Medication Therapy in Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, 2022-2031 (US$ Million)

Figure 9 Oxygen Therapy in Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, 2022-2031 (US$ Million)

Figure 10 Smoking Cessation Therapy in Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, 2022-2031 (US$ Million)

Figure 11 Others Therapy in Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, 2022-2031 (US$ Million)

Figure 12 Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Y-o-Y Growth, By Route of Administration, 2022-2031 (%)

Figure 13 Inhaled Route of Administration in Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, 2022-2031 (US$ Million)

Figure 14 Intravenous in Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, 2022-2031 (US$ Million

Figure 15 Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Y-o-Y Growth, By End User, 2022-2031 (%)

Figure 16 Hospitals End User in Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, 2022-2031 (US$ Million)

Figure 17 Ambulatory Surgical Centers End User in Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, 2022-2031 (US$ Million)

Figure 18 Others End User in Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, 2022-2031 (US$ Million)

Figure 19 Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure 20 North America Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, 2022-2031 (US$ Million)

Figure 21 Asia-Pacific Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, 2022-2031 (US$ Million)

Figure 22 Europe Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, 2022-2031 (US$ Million)

Figure 23 South America Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, 2022-2031 (US$ Million)

Figure 24 Middle East and Africa Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, 2022-2031 (US$ Million)

Figure 25 North America Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, 2022-2031 (US$ Million)

Figure 26 North America Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Share, By Treatment, 2022 & 2031 (%)

Figure 27 North America Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 28 North America Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Share, By End User, 2022 & 2031 (%)

Figure 29 North America Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Share, By Country, 2022 & 2031 (%)

Figure 30 South America Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, 2022-2031 (US$ Million)

Figure 31 South America Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Share, By Treatment, 2022 & 2031 (%)

Figure 32 South America Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 33 South America Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Share, By End User, 2022 & 2031 (%)

Figure 34 South America Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Share, By Country, 2022 & 2031 (%)

Figure 35 Europe Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, 2022-2031 (US$ Million)

Figure 36 Europe Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Share, By Treatment, 2022 & 2031 (%)

Figure 37 Europe Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 38 Europe Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Share, By End User, 2022 & 2031 (%)

Figure 39 Europe Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Share, By Country, 2022 & 2031 (%)

Figure 40 Asia-Pacific Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, 2022-2031 (US$ Million)

Figure 41 Asia-Pacific Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Share, By Treatment, 2022 & 2031 (%)

Figure 42 Asia-Pacific Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 43 Asia-Pacific Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Share, By End User, 2022 & 2031 (%)

Figure 44 Asia-Pacific Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Share, By Country, 2022 & 2031 (%)

Figure 45 Middle East & Africa Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Value, 2022-2031 (US$ Million)

Figure 46 Middle East & Africa Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Share, By Treatment, 2022 & 2031 (%)

Figure 47 Middle East & Africa Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 48 Middle East & Africa Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market Share, By End User, 2022 & 2031 (%)

Figure 49 Kamada Pharmaceuticals: Financials

Figure 50 Takeda Pharmaceutical Company Limited: Financials

Figure 51 CSL: Financials

Figure 52 Vertex Pharmaceuticals Incorporated: Financials

Figure 53 Grifols: Financials

Figure 54 Arrowhead Pharmaceuticals, Inc.: Financials

Figure 55 Dicerna Pharmaceuticals, Inc.: Financials

Figure 56 Inhibrx, Inc.: Financials

Figure 57 Wave Life Sciences: Financials

Figure 58 Mereo Biopharma Group PLC: Financials

글로벌 1형 알파-1 항트립신 결핍증 치료 시장 – 2023-2030

Global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market - 2023-2030